Zacks Investment Research on MSN

Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why

Shares of Protagonist Therapeutics PTGX have gained nearly 7% over the past week. The upside came after the company announced ...

Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

Protagonist's pipeline leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation. Find out ...
Fierce Pharma

J&J, Protagonist's 'game-changer' once-daily psoriasis pill Icotyde nabs FDA approval

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...

Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone

Protagonist Therapeutics (NASDAQ:PTGX) executives said March 18 that the U.S. Food and Drug Administration has approved ...
FierceBiotech

J&J, Protagonist's oral psoriasis prospect scores in phase 3 pair, readying case against BMS' Sotyktu

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...
BioSpace

Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights

Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million ...
Benzinga.com

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...